This page contains a Flash digital edition of a book.
could develop shingles in their lifetime if they are among the 90% that have had chickenpox1,2


1in 4 1in 4


of your adult patients


Prevention of shingles and post-herpetic neuralgia – 1 dose*


for adults aged 50+


ABRIDGED PRESCRIBING INFORMATION ZOSTAVAX®


▼powder and solvent for suspension for injection [shingles (herpes zoster)


vaccine (live)] Refer to Summary of Product Characteristics for full product information. Presentation: Vial containing a lyophilised preparation of live attenuated varicella-zoster virus (Oka/Merck strain) and a pre-fi lled syringe containing water for injections. After reconstitution, one dose contains no less than 19400 PFU (Plaque-forming units) varicella-zoster virus (Oka/ Merck strain). Indications: Active immunisation for the prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN) in individuals 50 years of age and older. Dosage and administration: A single dose should be administered by subcutaneous injection, preferably in the deltoid region. Contraindications: Hypersensitivity to the vaccine or any of its components (including neomycin).


Individuals receiving


immunosuppressive therapy (including high-dose corticosteroids) or who have a primary or acquired immunodefi ciency.


Individuals with active untreated tuberculosis. Pregnancy. Warnings and precautions: Appropriate facilities and medication should be available in SmPC, 2011.


the rare event of anaphylaxis. Deferral of vaccination should be considered in the presence of fever. In clinical trials with Zostavax, transmission of the vaccine virus has not been reported. However, post-marketing experience with varicella vaccines suggest that transmission of vaccine virus may occur rarely between vacinees who develop a varicella-like rash and susceptible contacts (for example, VZV-susceptible infant grandchildren). Transmission of vaccine virus from varicella vaccine recipients without a varicella-zoster virus (VZV)-like rash has been reported but has not been confi rmed. This is a theoretical risk for vaccination with Zostavax. The risk of transmitting the attenuated vaccine virus from a vaccinee to a susceptible contact should be weighed against the risk of developing natural zoster and potentially transmitting wild-type VZV to a susceptible contact. As with any vaccine, vaccination with Zostavax may not result in protection in all vaccine recipients. Pregnancy and lactation: Zostavax is not intended to be administered to pregnant women. Pregnancy should be avoided for three months following vaccination. Caution should be exercised if Zostavax is administered to a breast-feeding woman. Undesirable effects: Very common side effects include: pain/tenderness, erythema and


References: 1. Miller E, Marshall R, Vudien J. Epidemiology, outcome and control of varicella-zoster infection.Rev Med Microbiol 1993; 4: 222-30. 2. Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population.Eur J Pain 1999; 3: 335-42. 3. ZOSTAVAX®


* The need for a second dose is currently unknown 3


swelling at the injection site. Common side effects include pruritus, warmth and haematoma at the injection site and headache. Post marketing use has shown hypersensitivity reactions including anaphylactic reactions, joint and muscle pain, fever, swollen glands, rash, also hives and rash at the injection site. For a complete list of undesirable effects please refer to the Summary of Product Characteristics. Package quantities and basic NHS cost: Vial and pre-fi lled syringe with two separate needles. This vaccine is currently not available through the NHS. Marketing authorisation holder: Sanofi Pasteur MSD SNC, 8 Rue Jonas Salk, F-69007 Lyon, France Marketing authorisation number: EU/1/06/341/011 Legal category: POM ®


Registered trademark Date of last review: August 2011


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Sanofi Pasteur MSD, telephone number 01628 785291.


Zostavax®


Scan the QR code above with your smartphone to access www.shinglesaware.co.uk


cannot currently be prescribed on an NHS prescription (FP10) but can still be made available to your patients using a private prescription. UK15206 f 01/12


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84